Population: Fragile population

Individuals who are more vulnerable to poor health outcomes due to factors like chronic illness, weakened immune systems, disabilities or socioeconomic disadvantages

Pfizer C5091017

Argentina Belgium Brazil Bulgaria Canada China Czechia Denmark Finland Germany Japan Mexico Slovakia South Africa South Korea Spain Taiwan Türkiye United States of America
|
2024-2028
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Adolescents (12-17 years)
  • Outpatient clinic
  • Primary care
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Ibuzatrelvir

Ziegler

Austria Belgium Germany Sweden United Kingdom
|
2024-2027
  • Infants (<1 year)
  • Fragile population
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Pharmacological intervention
  • Vaccination

Mico-Cerda

Spain
|
2013-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • Respiratory syncytial virus

Redjoul

France
|
2024-2024
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • Respiratory syncytial virus
  • Pharmacological intervention
  • Vaccination

Raguž

Bosnia and Herzegovina
|
2008-2022
  • Infants (<1 year)
  • Fragile population
  • Hospital
  • Respiratory syncytial virus
  • Pharmacological intervention
  • Monoclonal antibodies
  • Palivizumab

Havlin

Czech Republic
|
2024-2024
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • Respiratory syncytial virus
  • Pharmacological intervention
  • Vaccination
  • Arexvy

Calomfirescu-Avramescu

Romania
|
2022-2024
  • Infants (<1 year)
  • Fragile population
  • Hospital
  • Respiratory syncytial virus
  • Pharmacological intervention
  • Monoclonal antibodies
  • Palivizumab

Paraskevis

Greece
|
2022-2022
  • Elderly (≥65 years)
  • Fragile population
  • Outpatient clinic
  • Community
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Nirmatrelvir/Ritonavir
  • Molnupiravir

Pinchera

Italy
|
2023-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Infectious diseases unit
  • SARS-CoV-2
  • Pharmacological intervention
  • Monoclonal antibodies
  • Tixagevimab/Cilgavimab

Orth

Germany
|
2022-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Hospital
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Remdesivir
  • Nirmatrelvir/Ritonavir
  • Molnupiravir
  • Sotrovimab
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab

Aguareles

Spain
|
2022-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Plitidepsin

Cuadrado-Payán

Spain
|
2021-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Hospital
  • Outpatient clinic
  • Community
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Remdesivir